

# Shattuck Labs & Takeda



Advancing a novel approach to develop next-generation immuno-oncology therapies



## Vision

To develop a next-generation immuno-oncology approach leveraging Shattuck Labs' Agonist Redirected Checkpoint (ARC) platform



## Partnership Approach


Equity investment and research collaboration with an option to enter into an exclusive license for global development and commercialization rights for certain ARC molecules resulting from the collaboration



## Partnership Terms

Takeda and Shattuck Labs entered into a research collaboration in 2017 to develop novel checkpoint fusion proteins with the goal of advancing differentiated, next-generation immuno-oncology therapies

Shattuck Labs was founded in 2016, partnered with Takeda with in 2017 and advanced SL-279252 (TAK-252) into the clinic in 2019



“Research partnerships are a key aspect of our continued dedication to oncology innovation, and this collaboration will bring us closer to our goal of discovering, developing and delivering breakthrough oncology therapies.”

– Chris Arendt, Head, Oncology Drug Discovery Unit, Takeda